Literature DB >> 3034031

Pharmacokinetics of ramipril in the elderly.

B H Meyer, F O Müller, M Badian, H G Eckert, P Hajdú, R Irmisch, D Schmidt.   

Abstract

Ramipril (HOE 498) is a pro-drug of which the main metabolite (HOE 498 diacid or ramiprilat) is a potent angiotensin converting enzyme inhibitor. Thirteen healthy white volunteers (5 females and 8 males, ages 65 to 76 years) participated in a study to investigate the pharmacokinetics of HOE 498 in the elderly. After administration of 10 mg of HOE 498, sequential urine and serum specimens were obtained for assay of HOE 498 and metabolites (HOE 498-glucuronide, diacid, diacid-glucuronide, diketopiperazine and diketopiperazine acid). Side effects, clinical chemistry and hematology were monitored. HOE 498 reached peak concentrations of 62.4 +/- 23.3 ng/ml in serum after 0.7 +/- 0.3 hours. Serum levels decreased with an apparent half-life of 0.9 +/- 0.4 hours. The diacid was rapidly formed in serum, reaching peak concentrations of 40.6 +/- 14.0 ng/ml after 2.0 +/- 0.6 hours and declining with a half-life of 2.2 +/- 0.5 hours. A prolonged terminal phase of serum concentration versus time curve was observed at concentrations less than 1 ng/ml. The mean recovery of HOE 498 and metabolites in urine, up to 26 hours after administration, was 35 +/- 14% of the dose. The apparent half-lives, calculated from urine parameters, for HOE 498 and the diacid were 2.6 +/- 0.9 and 4.0 +/- 1.1 hours, respectively. The mean peak concentration and half-life of HOE 498 in serum are slightly higher in the elderly than in younger volunteers. Complete urinary collection was not possible, but urinary recovery did not seem different from younger volunteers.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3034031     DOI: 10.1016/0002-9149(87)90050-6

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  13 in total

Review 1.  Cardiovascular drug therapy in elderly patients: specific age-related pharmacokinetic, pharmacodynamic and therapeutic considerations.

Authors:  Arduino A Mangoni
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 2.  Newer ACE inhibitors. A look at the future.

Authors:  A Salvetti
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

Review 3.  Optimal dosage of ACE inhibitors in older patients.

Authors:  B Tomlinson
Journal:  Drugs Aging       Date:  1996-10       Impact factor: 3.923

Review 4.  Clinical pharmacokinetics of the newer ACE inhibitors. A review.

Authors:  J G Kelly; K O'Malley
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

Review 5.  Ramipril. A review of its pharmacological properties and therapeutic efficacy in cardiovascular disorders.

Authors:  P A Todd; P Benfield
Journal:  Drugs       Date:  1990-01       Impact factor: 9.546

Review 6.  Angiotensin-converting enzyme inhibitors. Relationship between pharmacodynamics and pharmacokinetics.

Authors:  G G Belz; W Kirch; C H Kleinbloesem
Journal:  Clin Pharmacokinet       Date:  1988-11       Impact factor: 6.447

7.  Acute haemodynamic effects and pharmacokinetics of ramipril in patients with heart failure. A placebo controlled three-dose study.

Authors:  B Beermann; O Nyquist; C Höglund; K A Jacobsson; U Näslund; M Jensen-Urstad
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 8.  Clinical pharmacokinetics of vasodilators. Part I.

Authors:  R Kirsten; K Nelson; D Kirsten; B Heintz
Journal:  Clin Pharmacokinet       Date:  1998-06       Impact factor: 6.447

Review 9.  Clinical pharmacokinetics of ramipril.

Authors:  S Meisel; A Shamiss; T Rosenthal
Journal:  Clin Pharmacokinet       Date:  1994-01       Impact factor: 6.447

10.  A pharmacokinetic study of cilazapril in elderly and young volunteers.

Authors:  P E Williams; A N Brown; S Rajaguru; G E Walters; J McEwen; C Durnin
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.